Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
A novel electronic nose technique has been successfully used to discriminate between prostate cancer and benign prostatic hyperplasia in a proof-of-principle study. The eNose system demonstrated sensitivity and specificity comparable to traditional testing methods, such as prostate-specific antigen (PSA), with rapid and non-invasive re...
Research refines association between cardiovascular disease risk factors and prostate cancer, highlighting LDL cholesterol and triglycerides as key players. The study identifies 17 related gene loci that contribute to both high blood lipid levels and prostate cancer risk.
Researchers at Michigan Medicine have found that BET bromodomain protein 4 binds to the hormone androgen receptor, making it a potential target for prostate cancer treatment. The study suggests that a drug targeting this protein could work even when prostate cancer becomes resistant to current therapies.
A study found that chronic inflammation in benign prostate tissue was associated with high-grade prostate cancer. Men with at least one biopsy core showing inflammation had a 1.78 times higher odds of having prostate cancer and a 2.24 times higher odds of having aggressive disease.
A new study found that chronic inflammation in non-cancerous prostate tissue may increase a man's risk of developing high-grade prostate cancer by nearly twice. The study showed that men with signs of chronic inflammation had a higher risk of having an aggressive and rapidly growing prostate cancer.
A new method using existing ultrasound scanners allows doctors to accurately detect prostate cancer with much greater precision, reducing the need for painful biopsies. The technique saves money by eliminating costly biopsy analysis and can potentially eliminate biopsies altogether.
Researchers develop a technique to trick prostate cancer cells into using more glucose for imaging via PET scans, reducing the need for repeated biopsies. This method has potential therapeutic applications by cutting off cancer cells' energy supply from lipids.
Researchers found that circumcised men were 45% less at risk of developing prostate cancer than uncircumcised men. The protective effect was strongest among black men, who were 60% less likely to develop the disease if circumcised after age 35.
A clinical trial found that six months of hormone therapy added to radiotherapy significantly reduces the risk of prostate cancer relapse and progression. Men who received both treatments had a nearly 50% lower risk of biochemical progression compared to those treated with radiotherapy alone.
A study found that permanent brachytherapy preserves erectile function in approximately 50% of prostate cancer patients, improving treatment outcomes. Researchers call for further training on discussing and assessing sexual side-effects of radiation treatment to ensure adequate patient information.
Researchers developed a genetic signature to identify men at high risk of prostate cancer recurrence after surgery or radiotherapy. The test uses DNA analysis from biopsy tissue and shows promise in predicting treatment failure with close to 80% accuracy.
A recent study published in JAMA found that taking daily tadalafil did not prevent erectile dysfunction (ED) in men undergoing radiation therapy for prostate cancer. The study involved 242 men who received either tadalafil or a placebo, and showed no significant difference in ED prevention between the two groups.
New research by USC Norris Comprehensive Cancer Center scientists suggests that elevated CTC counts after chemotherapy indicate a higher risk of death, while reduced CTCs cut the risk in half. This study demonstrates CTCs as an important biomarker for cancer research and treatment.
QUT Professor Colleen Nelson leads an international team of researchers in developing new drugs and treatments for aggressive prostate cancer. The team aims to understand the impact of current treatments on metabolic dysfunction and patient wellbeing, with the goal of improving treatment outcomes.
A comprehensive study of over 15,000 men with localized prostate cancer found that primary androgen deprivation therapy does not extend survival. The treatment is associated with serious adverse events and mitigates against its use as a primary treatment option.
Researchers found that MicroRNA-34 can suppress prostate cancer when paired with p53, but not individually. The study used mice models and found that combined silencing of miR-34 and p53 led to uncontrolled stem cell growth and high levels of cancer.
The number of PSA screenings performed by doctors declined significantly after the 2012 USPSTF recommendations, with a greater impact seen among urologists.
Research from Umeå University and Memorial Sloan Kettering Cancer Center found that frequent PSA testing in areas with high incidence rates results in lower prostate cancer mortality. However, this is offset by increased risk of overtreatment, which can lead to side effects such as erectile dysfunction and urinary incontinence.
A new study by Yale University researchers found that a faster and less expensive form of radiotherapy for treating prostate cancer may come with a higher rate of urinary complications. Stereotactic body radiotherapy (SBRT) is a newer treatment option that can be completed in one to two weeks, compared to seven to nine weeks for intens...
A new approach to prostate cancer screening is needed, focusing on high-risk men rather than the entire population. The risk-based approach uses a computer-generated calculator that assesses factors like PSA levels, family history, and ethnicity to identify those at greatest risk.
Scientists at the University of Surrey have developed a new test to detect prostate and bladder cancers, showing twice the effectiveness of the existing PSA blood test. The EN2 biomarker test is being commercialized by Randox Laboratories and could lead to faster detection and cost savings.
A new study finds that radical prostatectomy reduces mortality in men under 65, while still benefiting older men by reducing metastases and treatment needs. The research used data from the Scandinavian Prostate Cancer Group Study Number 4, which randomized 695 men to surgery or watchful waiting with no initial treatment.
Researchers have found a link between prostate cancer aggressiveness and cholesteryl ester accumulation, suggesting new diagnostic and treatment methods. The study also shows that drugs previously developed to treat atherosclerosis might be repurposed for advanced prostate cancer treatment.
The PROCEDE 500 study demonstrates that the Prolaris test provides personalized risk assessment for prostate cancer patients, leading to significant changes in treatment plans. The study found a 50% reduction in surgical interventions and a 30% reduction in radiation treatment.
Patient satisfaction with treatment is greater when outcome information is specific to their treating physician, according to a study. This type of information helps patients set realistic expectations and make informed decisions about therapy selection.
Researchers found higher levels of BPA in prostate cancer patients than non-prostate cancer patients, with low-dose exposure linked to centrosome amplification and cell transformation. The study suggests a previously unknown relationship between BPA exposure and prostate cancer development.
A UCLA study published in European Urology found that robotic-assisted prostate surgery resulted in 5% fewer positive margins and a one-third reduction in the likelihood of needing additional cancer therapies. This suggests that robotic-assisted radical prostatectomy may offer better cancer control with potentially lower downstream costs.
University of Houston scientists identify AMPK enzyme's role in prostate cancer progression and metabolic changes. Their findings suggest that targeting metabolic pathways could lead to more effective cancer treatments.
The trial found that men treated with the more intensive radiotherapy regime had a 55% survival rate without disease progression, compared to 43%. The study also showed that dose-escalated radiotherapy reduces the need for follow-up hormone treatment and is safe in the long term.
A study published in the Journal of the National Cancer Institute found that high-dose supplementation with selenium and vitamin E increases the risk of high-grade prostate cancer in men. The risk depends on a man's baseline selenium level, with men who have low levels experiencing a higher risk
A new study published in JNCI Journal of the National Cancer Institute found that high-dose selenium supplementation increased the risk of high-grade prostate cancer among older men with high baseline toenail selenium concentrations. Vitamin E supplementation also raised PC risk, especially among men with low baseline selenium levels.
Scientists at The Institute of Cancer Research have discovered that screening for certain genetic mutations in men with a family history of prostate cancer can predict the development of aggressive forms of the disease. The study identified 13 'loss of function' mutations in eight DNA repair genes, which significantly increase the risk...
Researchers discovered that SPOP protein selectively destroys androgen receptor, a master regulator of prostate cancer cell growth. This finding sheds light on a new mechanism by which prostate cancer develops.
Scientists have discovered how the prostate gland develops for the first time, identifying 80 genes and a signalling pathway involved in its growth. The finding provides potential targets for new therapies to combat common prostate diseases, including prostate cancer.
A new study found that 3D mapping biopsies detect nearly three times as many cancerous zones in prostate cancer patients compared to ultrasound-guided biopsies. The study suggests that 3D mapping biopsies can accurately assess the location, stage, and risk of prostate cancer, leading to more targeted treatment options.
Dormant prostate cancer cells in bone tissue can be reactivated to form secondary tumors when exposed to the signaling molecule RANKL. Researchers have discovered that this reactivation process may lead to metastatic prostate cancer in bones, and targeting it could prevent metastasis and improve survival rates.
The PROCEDE 500 clinical utility study demonstrates the significant clinical value of Prolaris to physicians treating men with prostate cancer. The test accurately predicts prostate cancer-specific death and metastases, guiding treatment decisions and reducing therapeutic burden on patients.
Researchers have developed a new mouse model for metastatic prostate cancer, called RapidCaP, which reveals a specific role for Myc as a driver of metastasis in prostate cancer. The study suggests that targeting the Myc gene may provide a new approach to cure incurable prostate cancer.
A new study published in the Journal of Urology reports that prostate cancer patients treated with androgen deprivation therapy (ADT) experienced changes in mental and emotional well-being during treatment, with no significant decline in emotional quality of life two years after treatment. Investigators recommend counseling men about p...
Research suggests that walking at a brisk pace prior to diagnosis may improve prostate cancer outcomes by having more regularly shaped blood vessels. Men with faster walking paces had 8% more regularly shaped blood vessels compared to those with slower paces.
A study of Icelandic men found that higher melatonin levels were associated with a 75% reduced risk for developing advanced prostate cancer. Men who reported sleep problems had lower melatonin levels, suggesting the importance of maintaining a stable sleep-wake cycle.
Researchers at Penn State will receive $651,000 to create a method for identifying a prostate cancer-specific drug and developing a biodegradable nanoparticle capable of targeting the disease. The goal is to create an alternative to chemotherapy with reduced side effects.
A research group at Biocenter Oulu in Finland has identified a mechanism related to a transcription factor that binds strongly onto a particular SNP variant, initiating a genetic programme enhancing prostate cancer proliferation and metastasis. The study used DNA samples from tens of thousands of prostate cancer patients and healthy me...
Researchers developed a nomogram to predict likelihood of overdiagnosis based on age, PSA level, and Gleason score. The tool aims to help patients and clinicians make informed decisions about treatment options.
A study from the University of Illinois Chicago found that fetal exposure to BPA increases the risk for prostate cancer later in life. Human prostate tissue is susceptible to BPA, which mimics estrogen and has been linked to several cancers.
A new nomogram developed by Roman Gulati et al. estimates the likelihood of overdiagnosis for screen-detected prostate cancers, considering patient age, Gleason score, and PSA level at diagnosis. The model predicts risks ranging from 2.9% to 88.1% depending on individual characteristics.
A study published in Oncogene found that androgens hijack the AMPK signaling cascade to increase prostate cancer cell growth. This metabolic switch has significant implications for understanding early and late-stage prostate cancer progression.
Researchers will investigate racial and ethnic differences in IRDS-positive tumors prevalent in African-Americans to improve outcomes for patients with treatment-resistant prostate cancer. The study aims to identify new management and treatment options for this aggressive disease.
A Mayo Clinic-led study found that pain drugs used in prostate gland removal may be linked to cancer outcomes, as they can suppress the immune system's ability to fight cancer cells. The research suggests that a specific technique using opioids may reduce the risk of cancer recurrence and mortality.
A new optical sensor created at MIT can track zinc within cells, shedding light on its functions and helping researchers study zinc trafficking in prostate cells. The sensor supports the theory that cancerous prostate cells banish zinc from mitochondria to produce extra energy.
A study published online in Cancer found that increased inflammation in the prostate gland may predict a reduced risk of developing prostate cancer. The study's findings suggest that biopsies performed on prostates with high inflammation levels may indicate a lower risk for subsequent cancer detection.
Researchers have identified a potential biological factor contributing to racial disparities in prostate cancer incidence and mortality. Advanced glycation end-products (AGEs) accumulate in African-American men with prostate cancer, promoting inflammation and cancer progression. AGE levels correlated with receptor for AGE (RAGE), sugge...
Researchers identified a biomarker for prostate cancer recurrence, revealing that patients with CD151free protein have cancer recur earlier than those without. This discovery may aid in determining patient care and predicting disease progression.
Researchers found that 53% of men with ERG-positive HGPIN biopsies developed invasive prostate cancer, compared to 35% of those with ERG-negative biopsies. The discovery may help physicians monitor men at higher risk for cancer development and reduce unnecessary future biopsies.
A new study found that men with a specific genetic mutation are more than 50% likely to die from prostate cancer if they're overweight or obese. The researchers analyzed data on 1,243 participants and discovered that obesity was linked to higher levels of insulin and growth factor receptors in tumors containing the mutation.
Researchers at Henry Ford's Vattikuti Urology Institute found instances of ureteral injury in 6,442 patients who underwent robotic prostatectomy. Patient characteristics such as infection history, abdominal surgery, and enlarged prostate glands may forewarn such damage.
Men with prostate cancer who followed a low-fat fish oil diet had lower levels of pro-inflammatory substances in their blood and a lower cell cycle progression score compared to those on a Western diet. The study suggests that altering the diet may favorably affect prostate cancer biology.
Researchers have identified large oncosomes as a potential indicator of patients with more aggressive, treatment-resistant disease. The study also found that microRNA in these vesicles can influence tumor progression.
Researchers developed predictive models to forecast genito-urinary (GU) toxicity and erectile dysfunction in prostate cancer patients after high-dose radiotherapy. Smoking and dosimetric factors were key predictors of acute urinary symptoms, with the model confirmed by a larger cohort analysis.
A new study suggests that treatment of pelvic nodes individualized by including sentinel nodes can be easily integrated into an IMRT-based strategy, correctly covering individual pelvic nodes without nodal recurrence. The study's findings indicate low toxicity and efficacy, justifying further evaluation.